Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin can be started simultaneously with diet.

In adult patients without clinically evident CHD, but with multiple risk factors for CHD such as age, smoking, hypertension, low HDL-C, or a family history of early CHD, Attic® is indicated to:

In patients with type 2 diabetes, and without clinically evident CHD, but with multiple risk factors for CHD such as retinopathy, albuminuria, smoking, or hypertension, Attic® is indicated to:

In patients with clinically evident CHD, Attic® is indicated to:

Attic® is indicated:

As an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apo B and triglyceride levels and to increase HDL-C in patients with primary hypercholesterolaemia (heterozygous familial and nonfamilial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb).

As adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV).

For the treatment of patients with primary dysbetalipoproteinaemia (Fredrickson Type III) who do not respond adequately to diet.

To reduce total cholesterol and LDL-C in patients with homozygous familial hypercholesterolaemia as an adjunct to other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.

As an adjunct to diet to reduce total cholesterol, LDL-C and apo B levels in boys and menarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolaemia, if after an adequate trial of diet therapy, the following findings are present:

LDL-C remains ≥ 190 mg/dl or

LDL-C remains ≥ 160 mg/dl and

There is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease (CVD) risk factors are present in the pediatric patient

Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate.